GenScript believes that CustomArray's oligonucleotide synthesis and microarray manufacturing technology will enable it to better serve its customers.
Invitae issued approximately $21.2 million in shares of its own common stock to former CombiMatrix shareholders.
The revenue increase was driven by higher test volumes in its reproductive health segment and improved test reimbursement across all segments.
The release of the financial results comes just days after molecular diagnostics firm Invitae announced it will acquire CombiMatrix.
Invitae is interested in companies that can contribute positively to its revenues in the next two to three quarters, according to CEO Sean George.
The acquisitions will enable Invitae to add reproductive health genetic testing to its portfolio and become what it calls a "comprehensive genomic information company."
The firm noted that its reproductive health test sales were up 32 percent year over year to $2.9 million, while volume for such tests were up 15 percent.
The firm reported $3.5 million in revenue for the three months ended Dec. 31, 2016, and $12.9 million for the full year.
The company can now market the test in New York, in addition to other areas of the country where it has already made the assay available.
The firm reported 29 percent growth in its overall testing revenues, driven mainly by higher reproductive test volume and higher per-test revenue.
Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.
The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.
Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.
In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.